

© 2023 The Joint Commission

Issue 41, December 20, 2023 Page | 2

The prepublication version of the requirements will be available online until June 30, 2024. After July 1, 2024, please access the new requirements in the E-dition or standards manual.

# Infection Prevention and Control (IC) chapter

#### Requirement

Standard IC.04.01.01 The hospital has a hospitalwide infection prevention and control program for the surveillance, prevention, and control of healthcare-associated infections (HAIs) and other infectious diseases.

**EP 1.** The hospital governing body, based on the recommendation of the medical staff and nursing leaders, appoints an infection preventionist(s) or infection control professional(s) qualified through education, training, experience, or certification in infection prevention to be responsible for the infection prevention and control program.

EP 2. The infection preventionist(s) or infection control professional(s) is responsible for the following: Development and implementation of hospitalwide infection surveill



Issue 41, December 20, 2023 Page | 4

Centers for Disease Control and Prevention. (2019, May).

U.S. Department of Health and Human Services.

https://www.cdc.gov/infectioncontrol/guidelines/disinfection/

Healthcare Infection Control Practices Advisory Committee. (2022, November 29).

<u>https://www.cdc.gov/infectioncontrol/guidelines/core-practices/index.html</u> \*Not a complete literature review.

# Requirement

Standard 05.01.01 H\Y \cgd]HU`Ny [cj Yfb]b[ VcXm]g UWVci bHUYY Zcf h\Y ]a d`Ya YbHUh]cb, dYfZcfa UbW, UbX sustainability of the infection prevention and control program.

**EP 1.** H\Y \cgd]HJ`Ng [cj Yfb]b[ VcXm]g fYgdcbg]V`Y Zcf h\Y ]a d`Ya YbHJh]cb, dYfZcfa UbW, UbX gi gHJ]bUV]]ImcZh\Y infection prevention and control program and provides resources to support and track the implementation, success, and sustainability of the program Ng UVM] ]hYg.

Note: To make certain that systems are in place and operational to support the program, the governing body provides access to information technology; laboratory services; equipment and supplies; local, state, and federal public health author]h]YgÑUXj ]gcf]Yg UbX U'Yffg, gi VK Ug h\Y 787Ng <YU'h\ 5'YfhBYfk cf\_ (<5B)/: 85 U'Yffg/ manufacturers' instructions for use; and guidelines used to inform policies.

**EP 2.** H\Y \cgd]HJ\NJ [cj Yfb]b[ VcXmYbgi fYg h\Uhh\Y dfcVYa g]XYbh]ZJYX Vmh\Y ]bZVW]cb prevention and control program are addressed in collaboration with hospital quality assessment and performance improvement leaders and other leaders (for example, the medical director, nurse executive, and administrative leaders).

#### Rationale

Because performance on infection control activities is closely tied to important clinical, quality, and financial outcomes for hospitals, the governing body must support the success and sustainability of the infection prevention and control program. The governing body must provide operational support for the program by allocating the structures, staff, financial and technical resources necessary to conduct infection prevention and control activities. HAY [cj Yfb]b[ VcXma i ghU'gc a cb]rcfh\Y dfc[fUa Ñg dfc[ress and work with hospital leaders on addressing infection prevention and control issues as part of the wider quality assurance and performance improvement efforts. Research suggests that organizations whose governing boards are engaged and regularly review data on health carel acquired infections and other quality metrics tend to perform better on these quality indicators.

## References:\*

Centers for Medicare & Medicaid Services. (2022, July 6).

(QSO-22-20-Hospitals). U.S. Department of Health & Human Services. <u>https://www.cms.gov/medicareprovider-enrollment-and-certificationsurveycertificationgeninfopolicy-and-memos-states-and/infection-prevention-and-control-and-antibiotic-stewardship-program-interpretive-guidance-update</u>

Jha, A., & Epstein, A. (2010). Hospital governance and the quality of care. , 29(1), 182ì 187. \*Not a complete literature review.

## Requirement

**Standard IC.06.01.01** The hospital implements its infection prevention and control program through surveillance, prevention, and control activities.

**EP 1.** Hc df]cf]h]nY h\Y dfc[fUa Ky UVMj ]h]Yg, h\Y \cgd]HU`]XYbh]Z]Yg f]g\_g Zcf]bZYVMjcb, WebHJa]bUh]cb, UbX YI dcgi fY that pose a risk to patients and staff based on the following:

Its geographic location, community, and population served

The care, treatment, and services it provides

The analysis of surveillance activities and other infection control datax



© 2023 The Joint Commission

R<sup>®</sup> Report

Issue 41, December 20, 2023 Page | 6

Shenoy, E. S., & Weber, D. J. (2021). Occupational health update: approach to evaluation of health care personnel and preexposure prophylaxis. , 35(3), 7171 734. Siegel, J.D., Rhinehart, E., Jackson, M., Chiarello, L., & Healthcare Infection Control Practices Advisory Committee. (2023, July).

. Centers for Disease Control and Prevention.

<u>https://www.cdc.gov/infectioncontrol/guidelines/isolation/index.html</u> \*Not a complete literature review.

# Introduction to Standard IC.07.01.01

While there is not a standardized definition for high-consequence infectious diseases or special pathogens, expert consensus defines these as novel or reemerging infectious agents that are easily transmitted from person-toperson, have limited or no medical countermeasures (such as an effective vaccine or prophylaxis), have a high mortality, require prompt identification and implementation of infection control activities (for example, isolation, special personal protective equipment), and require rapid notification to public health authorities and special action. Examples of high-consequence infectious diseases or special pathogens include MERS, novel influenzas, and Ebola or other viral hemorrhagic fever diseases. This list may change, however, to reflect current regional or global outbreaks or to include future emerging agents.

Hospitals can support their preparedness for high-consequence infectious diseases or special pathogens by XYj Y`cd]b[ UbX \Uj ]b[ fYUX]mUj U]'UV'Y h\Y Î =XYbtify-Isolate, =DZcfa Ï gHUbXUfX]nYX dfchc\A3g hz [4] XY ff [2] bf [4] 27 (2) JT [(0)7BD DZ the initial encounter with an infected or potentially infected yindividual when they enter the hospital with the relevant symptoms, exposure, or travel history. The protocols are base



Issue 41, December 20, 2023 Page | 8

A special thanks to the following panel members:

# Technical Advisory Panel (TAP) Members

John Hick, MD Vincent Hsu, MD, MPH, FSHEA, FACP Alexander Isakov, MD, MPH, FACEP, FAEMS Michael Klompas, MD, MPH Vikramjit Mukherjee, MD Vikramjit Mukherjee, MD Minda G. Nieblas, MD, MPH, FACOEM Terri Rebmann, PhD, RN, CIC, FAPIC Eritical Structures (ESDEMAGOR & ESDEMAGO.888 598.94 Td[(E)12.004irica f165.34 633.1-3.2/TT00 11 Tr 60.888 598.94 Td[(E)12.004irica f165.34 630.1-3.2/TT00 11 Tr 60.888 598.94 7d[(E)12.004irica f165.34 630.1-3.2/TT00 11 Tr 60.888 598.94 7d[(E)12.004irica f165.34 630.1-3.2/TT00 11 Tr 60.888 5

